AI assistant
Sending…
Traws Pharma, Inc. — Director's Dealing 2023
Jun 13, 2023
35199_dirs_2023-06-13_6fbc648a-a1d7-4a76-b63d-2941a284585e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Onconova Therapeutics, Inc. (ONTX)
CIK: 0001130598
Period of Report: 2023-06-12
Reporting Person: Guerin Mark Patrick (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-06-12 | Common Stock | M | 5500 | — | Acquired | 23691 | Direct |
| 2023-06-12 | Common Stock | F | 1575 | $1.137 | Disposed | 22116 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-06-12 | Restricted Stock Units | $ | M | 5500 | Disposed | Common Stock (5500) | Direct |
Footnotes
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: On June 10, 2022 the reporting person was granted 16,500 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary.
More from Traws Pharma, Inc.
Annual Report
2026
May 29
Proxy Solicitation & Information Statement
2026
May 29
Proxy Solicitation & Information Statement
2026
May 29
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 26
Regulatory Filings
2026
May 22
Regulatory Filings
2026
May 15
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
May 15
Regulatory Filings
2026
May 8